Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Non-Hodgkin Lymphoma — Faculty Presentation: Stephen M Ansell, MD, PhD

Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of non-Hodgkin lymphoma.

LEARNING OBJECTIVES

• Evaluate published clinical research establishing the efficacy and safety of Bruton tyrosine kinase (BTK) inhibitors as a component of first-line therapy for mantle cell lymphoma (MCL), and assess the current and potential clinical role of various BTK inhibitor-based strategies for patients newly diagnosed with the disease. 
• Appreciate the biological rationale for, available data with and current clinical role of covalent and noncovalent BTK inhibitors for relapsed/refractory (R/R) MCL, and discern how these agents can be appropriately and safely integrated into routine practice. 
• Identify patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy would be appropriate as a component of first-line treatment. 
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents in the care of patients with DLBCL and follicular lymphoma (FL), and use this information in patient-education discussions. 
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates for R/R DLBCL. 
• Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL, FL and MCL, and counsel appropriately selected patients regarding the potential benefits of this strategy. 
• Evaluate the mechanism of action of and available clinical trial findings with CD20 x CD3 bispecific antibodies for FL and DLBCL, and determine the role of these agents in current clinical management. 
• Recall new data with agents and strategies currently under investigation for various subtypes of non-Hodgkin lymphoma, and discuss ongoing clinical trial opportunities with eligible patients. 

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/NHL/Presentations/CME..

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Stephen M Ansell, MD, PhD
Chair, Division of Hematology
Dorotha W and Grant L Sundquist Professor in Hematologic Malignancies Research
Enterprise Deputy Director, Mayo Clinic Cancer Center
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota

Advisory Committees: Affimed GmbH; Contracted Research: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Pfizer Inc, Regeneron Pharmaceuticals Inc, Step Pharma, Takeda Pharmaceuticals USA Inc.

Brian T Hill, MD, PhD
Director, Lymphoid Malignancy Program
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Advisory Committees, Consulting Agreements and Contracted Research: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Novartis.

Release date: May 2025
Expiration date: May 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Abramson JS et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): A global phase 3, randomised, open-label trial. Lancet 2024;404(10466):1940-54. Abstract

Alderuccio JP et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial. Lancet Haematol 2025;12(1):e23-34. Abstract

Bartlett NL et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol 2025;43(9):1061-72. Abstract

Brooks TR et al. Real-world outcomes with bispecific T-cell engagers (REALBiTE) for relapsed or refractory large B-cell lymphoma: A multi-center, retrospective cohort study. ASH 2024;Abstract 111.

Caimi PF et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica 2024;109(4):1184-93. Abstract

Dickinson MJ et al. Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study. ASH 2024;Abstract 865.

Dreyling M et al. High-risk subgroups and MRD: An updated analysis of the phase 3 ECHO trial of acalabrutinib with bendamustine/rituximab in previously untreated mantle cell lymphoma. ASH 2024;Abstract 1626.

Dreyling M et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): A three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet 2024;403(10441):2293-306. Abstract

Duell J et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: Final 5-year efficacy and safety findings in the phase II L-MIND study. Haematologica 2024;109(2):553-66. Abstract

Gaballa S et al. Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: High complete responses seen in CAR-T-naive and CAR-T-exposed patients. ASH 2024;Abstract 868.

Hou J-Z et al. Escalating doses of AZD0486, a novel CD19xCD3 T-cell engager, result in high complete remissions with rapid clearance of minimal residual disease in patients with relapsed/refractory follicular lymphoma. ASH 2024;Abstract 341.

Jain P et al. Acalabrutinib with rituximab is highly effective first line treatment for older patients with mantle cell lymphoma. ASH 2024;Abstract 3038.

Kamdar MK et al. Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study. ASCO 2024;Abstract 7013.

Kumar A et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood 2025;145(5):497-507. Abstract

Lewis D et al. Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: Results from the international randomised controlled trial, Enrich. ASH 2024;Abstract 235.

Linton KM et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 2024;11(8):e593-605. Abstract

Nastoupil L et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Transcend FL 2-year follow-up. ASH 2024;Abstract 4387.

Neelapu SS et al. 5-year follow-up analysis from ZUMA-5: A phase 2 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-hodgkin lymphoma. ASH 2024;Abstract 864.

Phillips TJ et al. Glofitamab in relapsed/refractory mantle cell lymphoma: Results from a phase I/II study. J Clin Oncol 2025;43(3):318-28. Abstract

Riedell PA et al. Rapcabtagene autoleucel (YTB323) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Phase II trial clinical update. ASH 2024;Abstract 67.

Salles G et al. Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes. ASH 2024;Abstract 469.

Sehn LH et al. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. Blood 2025;145(7):708-19. Abstract

Sehn LH et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Results from a phase 3 study (inMIND). ASH 2024;Abstract LBA-1.

Thieblemont C et al. Clinical outcomes of patients with high-risk relapsed/refractory follicular lymphoma treated with tisagenlecleucel: Phase 2 ELARA 4-year update. ASH 2024;Abstract 3034.

Vose JM et al. 3-year update from the Epcore NHL-1 trial: Epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. ASH 2024;Abstract 4480.

Wang M et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2025;26(2):200-13. Abstract

Wang M et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL): Results from the final analysis of the MCL cohort of the open-label, phase 1, seamless design, multicenter Transcend NHL 001 (TRANSCEND) study. Transplant Cell Ther 2025;31(Suppl 2):207. Abstract

Wang M et al. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: Results from the phase 3, double-blind, placebo-controlled ECHO trial. EHA 2024;Abstract LB3439.

Wang M et al. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv 2024;8(17):4539-48. Abstract